Global Non-Hodgkin Lymphoma Treatment Market Size, Status and Forecast 2024-2031

Report ID: 922415 | Published Date: Feb 2026 | No. of Page: 115 | Base Year: 2025 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Impact of U.S Tarrifs Analyzed 2025 

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Immunotherapy
        1.2.3 Targeted Therapy
        1.2.4 Chemotherapy
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital Pharmacies
        1.3.3 Retail Pharmacies
        1.3.4 Online Pharmacies
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Non-Hodgkin Lymphoma Treatment Market Perspective (2016-2027)
    2.2 Non-Hodgkin Lymphoma Treatment Growth Trends by Regions
        2.2.1 Non-Hodgkin Lymphoma Treatment Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Non-Hodgkin Lymphoma Treatment Historic Market Share by Regions (2016-2021)
        2.2.3 Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Regions (2022-2027)
    2.3 Non-Hodgkin Lymphoma Treatment Industry Dynamic
        2.3.1 Non-Hodgkin Lymphoma Treatment Market Trends
        2.3.2 Non-Hodgkin Lymphoma Treatment Market Drivers
        2.3.3 Non-Hodgkin Lymphoma Treatment Market Challenges
        2.3.4 Non-Hodgkin Lymphoma Treatment Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue
        3.1.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue (2016-2021)
        3.1.2 Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Players (2016-2021)
    3.2 Global Non-Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Non-Hodgkin Lymphoma Treatment Revenue
    3.4 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio
        3.4.1 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin Lymphoma Treatment Revenue in 2020
    3.5 Non-Hodgkin Lymphoma Treatment Key Players Head office and Area Served
    3.6 Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
    3.7 Date of Enter into Non-Hodgkin Lymphoma Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Hodgkin Lymphoma Treatment Breakdown Data by Type
    4.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Type (2016-2021)
    4.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2022-2027)

5 Non-Hodgkin Lymphoma Treatment Breakdown Data by Application
    5.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Application (2016-2021)
    5.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
    6.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Type
        6.2.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
        6.2.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
        6.2.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
    6.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Application
        6.3.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
        6.3.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
        6.3.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
    6.4 North America Non-Hodgkin Lymphoma Treatment Market Size by Country
        6.4.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021)
        6.4.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
    7.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type
        7.2.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
        7.2.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
        7.2.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
    7.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application
        7.3.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
        7.3.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
        7.3.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
    7.4 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country
        7.4.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021)
        7.4.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
    8.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type
        8.2.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
    8.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application
        8.3.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
    8.4 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region
        8.4.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
    9.2 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type
        9.2.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
        9.2.2 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
        9.2.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
    9.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application
        9.3.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
        9.3.2 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
        9.3.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
    9.4 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country
        9.4.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021)
        9.4.2 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
    10.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type
        10.2.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
    10.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application
        10.3.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
    10.4 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country
        10.4.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Takeda Pharmaceutical Company Limited
        11.1.1 Takeda Pharmaceutical Company Limited Company Details
        11.1.2 Takeda Pharmaceutical Company Limited Business Overview
        11.1.3 Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Introduction
        11.1.4 Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.1.5 Takeda Pharmaceutical Company Limited Recent Development
    11.2 AstraZeneca
        11.2.1 AstraZeneca Company Details
        11.2.2 AstraZeneca Business Overview
        11.2.3 AstraZeneca Non-Hodgkin Lymphoma Treatment Introduction
        11.2.4 AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.2.5 AstraZeneca Recent Development
    11.3 Bayer
        11.3.1 Bayer Company Details
        11.3.2 Bayer Business Overview
        11.3.3 Bayer Non-Hodgkin Lymphoma Treatment Introduction
        11.3.4 Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.3.5 Bayer Recent Development
    11.4 Novartis AG
        11.4.1 Novartis AG Company Details
        11.4.2 Novartis AG Business Overview
        11.4.3 Novartis AG Non-Hodgkin Lymphoma Treatment Introduction
        11.4.4 Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.4.5 Novartis AG Recent Development
    11.5 Gilead Sciences
        11.5.1 Gilead Sciences Company Details
        11.5.2 Gilead Sciences Business Overview
        11.5.3 Gilead Sciences Non-Hodgkin Lymphoma Treatment Introduction
        11.5.4 Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.5.5 Gilead Sciences Recent Development
    11.6 Spectrum Pharmaceuticals
        11.6.1 Spectrum Pharmaceuticals Company Details
        11.6.2 Spectrum Pharmaceuticals Business Overview
        11.6.3 Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
        11.6.4 Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.6.5 Spectrum Pharmaceuticals Recent Development
    11.7 Teva Pharmaceutical Industries Ltd.
        11.7.1 Teva Pharmaceutical Industries Ltd. Company Details
        11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
        11.7.3 Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Introduction
        11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development
    11.8 Bristol Myers Squibb Company
        11.8.1 Bristol Myers Squibb Company Company Details
        11.8.2 Bristol Myers Squibb Company Business Overview
        11.8.3 Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Introduction
        11.8.4 Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.8.5 Bristol Myers Squibb Company Recent Development
    11.9 Janssen Pharmaceuticals
        11.9.1 Janssen Pharmaceuticals Company Details
        11.9.2 Janssen Pharmaceuticals Business Overview
        11.9.3 Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
        11.9.4 Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.9.5 Janssen Pharmaceuticals Recent Development
    11.10 Roche
        11.10.1 Roche Company Details
        11.10.2 Roche Business Overview
        11.10.3 Roche Non-Hodgkin Lymphoma Treatment Introduction
        11.10.4 Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.10.5 Roche Recent Development
    11.11 CELGENE CORPORATION (Bristol Myers Squibb Company)
        11.11.1 CELGENE CORPORATION (Bristol Myers Squibb Company) Company Details
        11.11.2 CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
        11.11.3 CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Introduction
        11.11.4 CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.11.5 CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
    11.12 Merck & Co., Inc.
        11.12.1 Merck & Co., Inc. Company Details
        11.12.2 Merck & Co., Inc. Business Overview
        11.12.3 Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Introduction
        11.12.4 Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.12.5 Merck & Co., Inc. Recent Development
    11.13 Kyowa Kirin Co., Ltd.
        11.13.1 Kyowa Kirin Co., Ltd. Company Details
        11.13.2 Kyowa Kirin Co., Ltd. Business Overview
        11.13.3 Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Introduction
        11.13.4 Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.13.5 Kyowa Kirin Co., Ltd. Recent Development
    11.14 AbbVie
        11.14.1 AbbVie Company Details
        11.14.2 AbbVie Business Overview
        11.14.3 AbbVie Non-Hodgkin Lymphoma Treatment Introduction
        11.14.4 AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.14.5 AbbVie Recent Development
    11.15 Sanofi
        11.15.1 Sanofi Company Details
        11.15.2 Sanofi Business Overview
        11.15.3 Sanofi Non-Hodgkin Lymphoma Treatment Introduction
        11.15.4 Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
        11.15.5 Sanofi Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Immunotherapy
    Table 3. Key Players of Targeted Therapy
    Table 4. Key Players of Chemotherapy
    Table 5. Key Players of Others
    Table 6. Global Non-Hodgkin Lymphoma Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Non-Hodgkin Lymphoma Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Non-Hodgkin Lymphoma Treatment Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Non-Hodgkin Lymphoma Treatment Market Share by Regions (2016-2021)
    Table 10. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Non-Hodgkin Lymphoma Treatment Market Share by Regions (2022-2027)
    Table 12. Non-Hodgkin Lymphoma Treatment Market Trends
    Table 13. Non-Hodgkin Lymphoma Treatment Market Drivers
    Table 14. Non-Hodgkin Lymphoma Treatment Market Challenges
    Table 15. Non-Hodgkin Lymphoma Treatment Market Restraints
    Table 16. Global Non-Hodgkin Lymphoma Treatment Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players (2016-2021)
    Table 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2020)
    Table 19. Ranking of Global Top Non-Hodgkin Lymphoma Treatment Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
    Table 23. Date of Enter into Non-Hodgkin Lymphoma Treatment Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2016-2021)
    Table 27. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Non-Hodgkin Lymphoma Treatment Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2016-2021)
    Table 31. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 38. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 39. Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2016-2021) & (US$ Million) 
    Table 50. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2022-2027) & (US$ Million) 
    Table 51. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 56. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 57. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. Takeda Pharmaceutical Company Limited Company Details
    Table 64. Takeda Pharmaceutical Company Limited Business Overview
    Table 65. Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Product
    Table 66. Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 67. Takeda Pharmaceutical Company Limited Recent Development
    Table 68. AstraZeneca Company Details
    Table 69. AstraZeneca Business Overview
    Table 70. AstraZeneca Non-Hodgkin Lymphoma Treatment Product
    Table 71. AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 72. AstraZeneca Recent Development
    Table 73. Bayer Company Details
    Table 74. Bayer Business Overview
    Table 75. Bayer Non-Hodgkin Lymphoma Treatment Product
    Table 76. Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 77. Bayer Recent Development
    Table 78. Novartis AG Company Details
    Table 79. Novartis AG Business Overview
    Table 80. Novartis AG Non-Hodgkin Lymphoma Treatment Product
    Table 81. Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 82. Novartis AG Recent Development
    Table 83. Gilead Sciences Company Details
    Table 84. Gilead Sciences Business Overview
    Table 85. Gilead Sciences Non-Hodgkin Lymphoma Treatment Product
    Table 86. Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 87. Gilead Sciences Recent Development
    Table 88. Spectrum Pharmaceuticals Company Details
    Table 89. Spectrum Pharmaceuticals Business Overview
    Table 90. Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
    Table 91. Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 92. Spectrum Pharmaceuticals Recent Development
    Table 93. Teva Pharmaceutical Industries Ltd. Company Details
    Table 94. Teva Pharmaceutical Industries Ltd. Business Overview
    Table 95. Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Product
    Table 96. Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 97. Teva Pharmaceutical Industries Ltd. Recent Development
    Table 98. Bristol Myers Squibb Company Company Details
    Table 99. Bristol Myers Squibb Company Business Overview
    Table 100. Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 101. Bristol Myers Squibb Company Recent Development
    Table 102. Janssen Pharmaceuticals Company Details
    Table 103. Janssen Pharmaceuticals Business Overview
    Table 104. Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
    Table 105. Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 106. Janssen Pharmaceuticals Recent Development
    Table 107. Roche Company Details
    Table 108. Roche Business Overview
    Table 109. Roche Non-Hodgkin Lymphoma Treatment Product
    Table 110. Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 111. Roche Recent Development
    Table 112. CELGENE CORPORATION (Bristol Myers Squibb Company) Company Details
    Table 113. CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
    Table 114. CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Product
    Table 115. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 116. CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
    Table 117. Merck & Co., Inc. Company Details
    Table 118. Merck & Co., Inc. Business Overview
    Table 119. Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Product
    Table 120. Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 121. Merck & Co., Inc. Recent Development
    Table 122. Kyowa Kirin Co., Ltd. Company Details
    Table 123. Kyowa Kirin Co., Ltd. Business Overview
    Table 124. Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Product
    Table 125. Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 126. Kyowa Kirin Co., Ltd. Recent Development
    Table 127. AbbVie Company Details
    Table 128. AbbVie Business Overview
    Table 129. AbbVie Non-Hodgkin Lymphoma Treatment Product
    Table 130. AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 131. AbbVie Recent Development
    Table 132. Sanofi Company Details
    Table 133. Sanofi Business Overview
    Table 134. Sanofi Non-Hodgkin Lymphoma Treatment Product
    Table 135. Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
    Table 136. Sanofi Recent Development
    Table 137. Research Programs/Design for This Report
    Table 138. Key Data Information from Secondary Sources
    Table 139. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-Hodgkin Lymphoma Treatment Market Share by Type: 2020 VS 2027
    Figure 2. Immunotherapy Features
    Figure 3. Targeted Therapy Features
    Figure 4. Chemotherapy Features
    Figure 5. Others Features
    Figure 6. Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2020 VS 2027
    Figure 7. Hospital Pharmacies Case Studies
    Figure 8. Retail Pharmacies Case Studies
    Figure 9. Online Pharmacies Case Studies
    Figure 10. Others Case Studies
    Figure 11. Non-Hodgkin Lymphoma Treatment Report Years Considered
    Figure 12. Global Non-Hodgkin Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 13. Global Non-Hodgkin Lymphoma Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 14. Global Non-Hodgkin Lymphoma Treatment Market Share by Regions: 2020 VS 2027
    Figure 15. Global Non-Hodgkin Lymphoma Treatment Market Share by Regions (2022-2027)
    Figure 16. Global Non-Hodgkin Lymphoma Treatment Market Share by Players in 2020
    Figure 17. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2020
    Figure 18. The Top 10 and 5 Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue in 2020
    Figure 19. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2016-2021)
    Figure 20. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2022-2027)
    Figure 21. North America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. North America Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
    Figure 23. North America Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
    Figure 24. North America Non-Hodgkin Lymphoma Treatment Market Share by Country (2016-2027)
    Figure 25. United States Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Canada Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
    Figure 29. Europe Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
    Figure 30. Europe Non-Hodgkin Lymphoma Treatment Market Share by Country (2016-2027)
    Figure 31. Germany Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. France Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. U.K. Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Italy Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Russia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Nordic Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
    Figure 39. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
    Figure 40. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Region (2016-2027)
    Figure 41. China Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Japan Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. South Korea Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Southeast Asia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. India Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Australia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
    Figure 49. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
    Figure 50. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Country (2016-2027)
    Figure 51. Mexico Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Brazil Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
    Figure 55. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
    Figure 56. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Country (2016-2027)
    Figure 57. Turkey Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Saudi Arabia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. UAE Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 61. AstraZeneca Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 62. Bayer Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 63. Novartis AG Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 64. Gilead Sciences Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 65. Spectrum Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 66. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 67. Bristol Myers Squibb Company Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 68. Janssen Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 69. Roche Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 70. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 71. Merck & Co., Inc. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 72. Kyowa Kirin Co., Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 73. AbbVie Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 74. Sanofi Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
    Figure 75. Bottom-up and Top-down Approaches for This Report
    Figure 76. Data Triangulation
    Figure 77. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Takeda Pharmaceutical Company Limited
AstraZeneca
Bayer
Novartis AG
Gilead Sciences
Spectrum Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb Company
Janssen Pharmaceuticals
Roche
CELGENE CORPORATION (Bristol Myers Squibb Company)
Merck & Co., Inc.
Kyowa Kirin Co., Ltd.
AbbVie
Sanofi
Frequently Asked Questions
Non-Hodgkin Lymphoma Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Non-Hodgkin Lymphoma Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Non-Hodgkin Lymphoma Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports